Synchron Secures US$200 Million in Series D Financing
Synchron has successfully raised US$200 million in a Series D funding round aimed at speeding up the commercialisation of its first-generation Stentrode brain-computer interface (BCI) platform. The funding will also support the development of a next-generation, transcatheter, high-channel whole-brain interface.
Key Objectives of the Funding
- Accelerate pivotal clinical trials
- Prepare for the commercial launch of the Stentrode BCI system
- Expand the team by hiring engineers, neuroscientists, and operators to drive innovation in BCI technology
Investment Details and Backers
The Series D round was led by Double Point Ventures, with participation from existing investors such as ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. It also attracted new investors including the Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
Company Statement
Synchron stated in a press release that, "bolstered by this Series D funding, it will continue hiring engineers, neuroscientists, and operators to advance the next generation of BCIs."
Funding Overview
This latest financing round brings Synchron’s total capital raised to US$345 million, supporting its mission to transform brain-computer interface technology.
Author's Summary: Synchron raises $200M to fast-track its Stentrode BCI commercialisation and develop advanced whole-brain interfaces, marking a significant milestone in neurotechnology innovation.
More News
- Indonesian police find writing, powder evidence pointing to student suspect in Jakarta school mosque blast as wounded nears 100
- Possible explosive powder found after Indonesian mosque blast, police say
- Jobs and education for the 21st century | READER COMMENTARY
- Opinion: School districts must confront tough choices to protect public education
- Graduate Student Loan Program Eliminated as Trump's Education Overhaul Hits Middle Class